{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:59:02Z","timestamp":1793019542409,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1111,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Tufts Clinical and Translational Science Institute","award":["NIH\/NCRR UL1RR025752"],"award-info":[{"award-number":["NIH\/NCRR UL1RR025752"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.jacc.2010.05.011","type":"journal-article","created":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T04:34:02Z","timestamp":1279686842000},"page":"392-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":466,"title":["Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction"],"prefix":"10.1016","volume":"56","author":[{"given":"Daniel G.","family":"Kramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Trikalinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George V.","family":"Antonopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin A.","family":"Konstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Udelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2010.05.011_bib1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1054\/j.cardfail.2003.09.001","article-title":"Ventricular remodeling in heart failure: a credible surrogate end point","volume":"9","author":"Konstam","year":"2003","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0167-5273(02)00182-1","article-title":"Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?","volume":"85","author":"Kalra","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(04)16723-8","article-title":"Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Anand","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.05.011_bib4","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib5","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.jacc.2010.05.011_bib7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1054\/jcaf.2002.129289","article-title":"Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction","volume":"8","author":"Udelson","year":"2002","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.76.1.44","article-title":"Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction","volume":"76","author":"White","year":"1987","journal-title":"Circulation"},{"issue":"Suppl 6","key":"10.1016\/j.jacc.2010.05.011_bib9","first-page":"65","article-title":"Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure","volume":"87","author":"Wong","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib10","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jacc.2003.12.053","article-title":"Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: valsartan heart failure trial (Val-HeFT) echocardiographic data","volume":"43","author":"Wong","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib11","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1016\/S0002-9149(88)80081-X","article-title":"Prognosis of congestive heart failure and predictors of mortality","volume":"62","author":"Cohn","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib12","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0002-9149(90)91434-8","article-title":"Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation","volume":"65","author":"Keogh","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib13","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/01.CIR.62.5.960","article-title":"Predictors of clinical course, coronary anatomy and left ventricular function after recovery from acute myocardial infarction","volume":"62","author":"Taylor","year":"1980","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198205063061801","article-title":"Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study","volume":"306","author":"Sanz","year":"1982","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.jacc.2010.05.011_bib15","first-page":"17","article-title":"Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure","volume":"87","author":"Cintron","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib16","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199507133330201","article-title":"Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia","volume":"333","author":"Singh","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib18","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib19","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.CIR.86.2.431","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure","volume":"86","author":"Konstam","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib21","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1161\/01.CIR.88.5.2277","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction","volume":"88","author":"Konstam","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cardfail.2007.03.001","article-title":"Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT","volume":"13","author":"Cohn","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib23","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.94.11.2800","article-title":"Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure","volume":"94","author":"Colucci","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1071-9164(00)00007-5","article-title":"Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease","volume":"6","author":"Doughty","year":"2000","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib25","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1161\/01.CIR.96.7.2197","article-title":"Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS)","volume":"96","author":"Lechat","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jama.282.8.771","article-title":"Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group","volume":"282","author":"Bucher","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.05.011_bib27","first-page":"I296","article-title":"Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure?","volume":"100","author":"Antonopoulos","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib28","series-title":"The Handbook of Research Synthesis","article-title":"Parametric Measures of Effect Size","author":"Rosenthal","year":"1994"},{"key":"10.1016\/j.jacc.2010.05.011_bib29","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jacc.2010.05.011_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trial"},{"key":"10.1016\/j.jacc.2010.05.011_bib31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","article-title":"Quantitative synthesis in systematic reviews","volume":"127","author":"Lau","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib32","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2010.05.011_bib34","series-title":"Mathematical Methods of Statistics","author":"Cramer","year":"1999"},{"key":"10.1016\/j.jacc.2010.05.011_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9149(76)90491-4","article-title":"Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy","volume":"37","author":"Teichholz","year":"1976","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib36","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib37","first-page":"17","article-title":"Mean body weight, height, and body mass index, United States 1960-2002","volume":"347","author":"Ogden","year":"2004","journal-title":"Adv Data"},{"key":"10.1016\/j.jacc.2010.05.011_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(02)02063-6","article-title":"Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study","volume":"40","author":"Wong","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib39","doi-asserted-by":"crossref","first-page":"20727","DOI":"10.1016\/S0735-1097(00)01006-8","article-title":"Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure","volume":"36","author":"Groenning","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-8703(99)70083-9","article-title":"Metoprolol CR\/XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction","volume":"138","author":"Goldstein","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib41","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1067\/mhj.2002.121269","article-title":"Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging","volume":"143","author":"Dubach","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib42","doi-asserted-by":"crossref","first-page":"25737","DOI":"10.1161\/01.CIR.91.10.2573","article-title":"Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction","volume":"91","author":"Greenberg","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/S1071-9164(00)00008-7","article-title":"Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change","volume":"6","author":"Wong","year":"2000","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib44","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.101.7.758","article-title":"Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study","volume":"101","author":"Levine","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib45","doi-asserted-by":"crossref","first-page":"21517","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib46","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","article-title":"Effect of amlodipine on morbidity and mortality in severe chronic heart failure","volume":"335","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.05.011_bib48","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.05.011_bib50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.05.011_bib51","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib52","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib53","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib54","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.05.011_bib55","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib56","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractionscongestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib57","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib58","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ejheart.2005.09.006","article-title":"Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE","volume":"7","author":"Cleland","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib59","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1161\/01.CIR.96.3.856","article-title":"Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III","volume":"96","author":"Cohn","year":"1997","journal-title":"Circulation"},{"issue":"Suppl","key":"10.1016\/j.jacc.2010.05.011_bib60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0002-8703(00)90075-9","article-title":"Design of phase II trials in congestive heart failure","volume":"139","author":"DeMets","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib61","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib62","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(96)10488-8","article-title":"Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure","volume":"349","author":"Hampton","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.05.011_bib63","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.05.011_bib64","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib65","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1388-9842(03)00163-6","article-title":"Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)","volume":"5","author":"Cohn","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib66","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib67","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.05.011_bib68","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/0735-1097(89)90030-2","article-title":"Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial","volume":"14","author":"Hamer","year":"1989","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib69","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/0002-9149(93)90291-J","article-title":"Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction","volume":"72","author":"Navarro-Lopez","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib70","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0002-8703(00)90095-4","article-title":"Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction","volume":"139","author":"Udelson","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib71","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0002-9149(90)90488-M","article-title":"Usefulness of bucindolol in congestive heart failure","volume":"66","author":"Pollock","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib72","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/01.CIR.84.6.2426","article-title":"Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy","volume":"84","author":"Woodley","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib73","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1161\/01.CIR.89.4.1632","article-title":"Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy","volume":"89","author":"Bristow","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib74","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/hc1102.105730","article-title":"Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling","volume":"105","author":"Saxon","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib75","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/01.CIR.0000065226.24159.E9","article-title":"Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure","volume":"107","author":"St John Sutton","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib76","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0735-1097(03)01042-8","article-title":"Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias","volume":"42","author":"Higgins","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib77","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1161\/01.CIR.0000146336.92331.D1","article-title":"Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure","volume":"110","author":"Abraham","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib78","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1388-9842(03)00162-4","article-title":"Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure","volume":"5","author":"Matsumori","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib79","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0735-1097(83)80316-7","article-title":"A placebo-controlled trial of captopril in refractory chronic congestive heart failure","volume":"2","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib80","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(88)90347-9","article-title":"Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction","volume":"1","author":"Sharpe","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.05.011_bib81","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/hrt.69.3.215","article-title":"Early treatment with captopril after acute myocardial infarction","volume":"69","author":"Ray","year":"1993","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib82","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0002-9149(92)91268-9","article-title":"Effects of captopril on left ventricular systolic and diastolic function after acute myocardial infarction","volume":"70","author":"Gotzsche","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib83","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jama.1988.03720040031022","article-title":"Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure","volume":"259","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.05.011_bib84","first-page":"90","article-title":"One-year clinical and echocardiographic follow-up of patients with congestive cardiomyopathy treated with captopril compared to placebo","volume":"30","author":"Keren","year":"1994","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.jacc.2010.05.011_bib85","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0735-1097(97)00012-0","article-title":"Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease","volume":"29","author":"Doughty","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib86","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0002-9149(96)00420-1","article-title":"Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy","volume":"78","author":"Quaife","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib87","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1161\/01.CIR.92.6.1499","article-title":"Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure","volume":"92","author":"Krum","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib88","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/01.CIR.92.2.212","article-title":"Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease","volume":"92","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib89","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/01.CIR.96.1.183","article-title":"Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction","volume":"96","author":"Basu","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib90","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0735-1097(95)00012-S","article-title":"Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study","volume":"25","author":"Olsen","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib91","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/0735-1097(94)90174-0","article-title":"Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy","volume":"24","author":"Metra","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib92","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0002-8703(96)90363-4","article-title":"Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure","volume":"131","author":"Krum","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib93","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(03)13801-9","article-title":"Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial","volume":"362","author":"Cleland","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.05.011_bib94","first-page":"29","article-title":"The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure","volume":"106","author":"Chizzola","year":"2006","journal-title":"In J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib95","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.fjc.0000159880.12067.34","article-title":"Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure","volume":"45","author":"Palazzuoli","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2010.05.011_bib96","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0002-9149(99)00059-4","article-title":"Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure","volume":"83","author":"Lowes","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib97","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejheart.2003.12.007","article-title":"Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure","volume":"6","author":"Cohen Solal","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib98","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1388-9842(02)00114-9","article-title":"Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure","volume":"4","author":"Palazzuoli","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib99","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib100","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.CIR.94.11.2793","article-title":"Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure","volume":"94","author":"Packer","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib101","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1071-9164(97)90013-0","article-title":"Safety and efficacy of carvedilol in severe heart failure","volume":"3","author":"Cohn","year":"1997","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib102","first-page":"324","article-title":"Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial","volume":"147","author":"Hori","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib103","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0002-8703(99)70148-1","article-title":"Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol","volume":"138","author":"Guazzi","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib104","first-page":"344","article-title":"A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy","volume":"21","author":"Tatli","year":"2005","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib105","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1388-9842(01)00141-6","article-title":"The effect of chronic digitalization on pump function in systolic heart failure","volume":"3","author":"Hassapoyannes","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2010.05.011_bib106","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0735-1097(93)90403-N","article-title":"Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial","volume":"22","author":"Uretsky","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib107","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1378\/chest.106.4.996","article-title":"Nonpharmacologic therapy improves functional and emotional status in congestive heart failure","volume":"106","author":"Kostis","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2010.05.011_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199307013290101","article-title":"Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors","volume":"329","author":"Packer","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib109","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM198903163201101","article-title":"A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure","volume":"320","author":"DiBianco","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0735-1097(85)80090-5","article-title":"Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure","volume":"5","author":"Franciosa","year":"1985","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2010.05.011_bib111","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2165\/00003495-198500301-00011","article-title":"Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure","volume":"30","author":"Webster","year":"1985","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2010.05.011_bib112","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/hrt.54.4.405","article-title":"Controlled trial of enalapril in congestive cardiac failure","volume":"54","author":"McGrath","year":"1985","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib113","doi-asserted-by":"crossref","first-page":"723","DOI":"10.5694\/j.1326-5377.1984.tb113232.x","article-title":"Enalapril for severe congestive heart failure","volume":"141","author":"Jennings","year":"1984","journal-title":"Med J Aust"},{"key":"10.1016\/j.jacc.2010.05.011_bib114","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/oxfordjournals.eurheartj.a060483","article-title":"Oral enoximone as a substitute for intravenous catecholamine support in end-stage congestive heart failure","volume":"15","author":"Jondeau","year":"1994","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib115","first-page":"266","article-title":"Augmentation of diastolic function with phosphodiesterase inhibition in congestive heart failure","volume":"114","author":"Binkley","year":"1989","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib116","doi-asserted-by":"crossref","first-page":"C75","DOI":"10.1016\/0002-9149(87)90531-5","article-title":"Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation","volume":"60","author":"Khalife","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib117","doi-asserted-by":"crossref","first-page":"C72","DOI":"10.1016\/0002-9149(87)90530-3","article-title":"A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure","volume":"60","author":"Zipperle","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib118","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1161\/01.CIR.76.6.1307","article-title":"Double-blind crossover comparison of enoximone and placebo in patients with congestive heart failure","volume":"76","author":"Choraria","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib119","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/0002-8703(91)90154-A","article-title":"Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial","volume":"121","author":"Narahara","year":"1991","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib120","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib121","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/hrt.73.5.428","article-title":"Placebo controlled trial of felodipine in patients with mild to moderate heart failure","volume":"73","author":"Littler","year":"1995","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib122","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00005344-199003000-00001","article-title":"Long-term clinical, hemodynamic, angiographic, and neurohumoral responses to vasodilation with felodipine in patients with chronic congestive heart failure","volume":"15","author":"Kassis","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2010.05.011_bib123","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0735-1097(93)90816-J","article-title":"Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure","volume":"22","author":"Packer","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib124","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/clc.4960130609","article-title":"Chronic vasodilator therapy with flosequinan in congestive heart failure","volume":"13","author":"Haas","year":"1990","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib125","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0002-9149(94)90680-7","article-title":"Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor","volume":"73","author":"Rousseau","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib126","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1067\/mhj.2002.121807","article-title":"Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure","volume":"144","author":"de Milliano","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib127","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/01.CIR.101.4.378","article-title":"Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study","volume":"101","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib128","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1161\/01.CIR.0000014212.04920.62","article-title":"Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure","volume":"105","author":"Swedberg","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib129","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/0002-9149(83)90310-7","article-title":"Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study","volume":"51","author":"Markham","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0002-9149(80)90656-6","article-title":"Long-term therapy of heart failure with prazosin: a randomized double blind trial","volume":"45","author":"Colucci","year":"1980","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib131","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/0002-9149(83)90415-0","article-title":"Long-term ambulatory therapy with prazosin versus placebo for chronic heart failure: relation between clinical response and left ventricular function at rest and during exercise","volume":"52","author":"Higginbotham","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib132","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"Cicoira","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib133","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib134","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib135","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0195-668X(02)00475-X","volume":"24","author":"Duncan","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.05.011_bib136","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM198807143190204","article-title":"Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction","volume":"319","author":"Pfeffer","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib137","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0735-1097(96)00113-1","article-title":"Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction?","volume":"28","author":"van Gilst","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib138","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1161\/01.CIR.87.4.1093","article-title":"Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction","volume":"87","author":"Sogaard","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib139","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/hrt.2003.015552","article-title":"Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study","volume":"90","author":"Bellenger","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2010.05.011_bib140","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"Cardiac remodeling\u2014concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib141","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1161\/01.CIR.101.25.2981","article-title":"Left ventricular remodeling after myocardial infarction: pathophysiology and therapy","volume":"101","author":"Sutton","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.05.011_bib142","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)01773-4","article-title":"Surrogate end points in heart failure","volume":"39","author":"Anand","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.05.011_bib143","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib144","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate end points in clinical trials: are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.05.011_bib145","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.0.CO;2-M","article-title":"Meta-analysis for the evaluation of potential surrogate markers","volume":"16","author":"Daniels","year":"1997","journal-title":"Stat Med"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710019182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710019182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:39:43Z","timestamp":1760013583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109710019182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":145,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0735109710019182"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2010.05.011","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2010.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}